[go: up one dir, main page]

NI201000030A - Formulaciones de liposomas de compuestos de ácidos borónico - Google Patents

Formulaciones de liposomas de compuestos de ácidos borónico

Info

Publication number
NI201000030A
NI201000030A NI201000030A NI201000030A NI201000030A NI 201000030 A NI201000030 A NI 201000030A NI 201000030 A NI201000030 A NI 201000030A NI 201000030 A NI201000030 A NI 201000030A NI 201000030 A NI201000030 A NI 201000030A
Authority
NI
Nicaragua
Prior art keywords
boronic acid
liposomes
compound
acid compounds
liposome formulations
Prior art date
Application number
NI201000030A
Other languages
English (en)
Inventor
Huang Anthony
Luo Bing
Wang Jinkang
Zhang Yuanpeng
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of NI201000030A publication Critical patent/NI201000030A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe una composición de liposomas que comprende liposomas con un compuesto inhibidor del proteasoma con péptido de ácido borónico atrapado en los liposomas. Mas específicamente, los liposomas que tienen un compuesto de la Fórmula I ó II atrapados en el compartimento acuoso interior se cargan con un compuesto peptídico de ácido borónico, para formar un compuesto de éster boronato dentro del compartimento acuoso liposomal. En una modalidad, los liposomas tienen un recubrimiento externo de cadenas poliméricas hidrófilas y se utilizan para tratar un tumor sólido en un sujeto.
NI201000030A 2007-08-21 2010-02-19 Formulaciones de liposomas de compuestos de ácidos borónico NI201000030A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95704907P 2007-08-21 2007-08-21

Publications (1)

Publication Number Publication Date
NI201000030A true NI201000030A (es) 2010-07-29

Family

ID=39772869

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000030A NI201000030A (es) 2007-08-21 2010-02-19 Formulaciones de liposomas de compuestos de ácidos borónico

Country Status (16)

Country Link
US (1) US20090092662A1 (es)
EP (1) EP2190412A2 (es)
JP (1) JP2010536875A (es)
KR (1) KR20100066515A (es)
CN (1) CN101795672A (es)
AU (1) AU2008288920A1 (es)
BR (1) BRPI0815713A2 (es)
CA (1) CA2697044A1 (es)
CO (1) CO6260057A2 (es)
EA (1) EA201070297A1 (es)
EC (1) ECSP109983A (es)
MX (1) MX2010002101A (es)
NI (1) NI201000030A (es)
SV (1) SV2010003487A (es)
WO (1) WO2009026430A2 (es)
ZA (1) ZA201002011B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10125388B2 (en) * 2007-10-31 2018-11-13 Akonni Biosystems, Inc. Integrated sample processing system
WO2009155135A1 (en) * 2008-06-18 2009-12-23 Alza Corporation Composition comprising liposome-entrapped doxorubicin and methods of admnistration for treatment of multiple myeloma
US9034829B1 (en) * 2011-10-27 2015-05-19 Northwestern University pH-sensitive polymer-drug conjugates for targeted delivery of therapeutics
CN111116622A (zh) 2014-02-03 2020-05-08 俄亥俄州创新基金会 硼酸酯和其药物制剂
AU2016256979B2 (en) 2015-05-04 2021-01-28 Versantis AG Method for preparing transmembrane pH-gradient vesicles
CN109045272A (zh) * 2018-08-01 2018-12-21 厦门市壳聚糖生物科技有限公司 一种硼替佐米磷脂复合物及其制备方法与应用
US20220387460A1 (en) * 2019-11-11 2022-12-08 Washington University Liposome compositions and methods of treatment targeted to tumor endothelium
KR20250049280A (ko) * 2022-08-12 2025-04-11 아비코 라디오파마슈티컬스, 엘엘씨 붕소 중성자 포획 요법을 위한 소분자
TW202421106A (zh) * 2022-09-21 2024-06-01 美商艾維克放射性藥物股份有限公司 用於硼中子捕獲療法之小分子

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003263333A1 (en) * 2002-09-09 2004-03-29 Trigen Limited Multivalent metal salts of boronic acids for treating thrombosis
US20060110439A1 (en) * 2004-10-22 2006-05-25 Dynamis Therapeutics, Inc. Dermal delivery of n-methyl-glucamine and n-methyl-glucamine compounds
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds

Also Published As

Publication number Publication date
CN101795672A (zh) 2010-08-04
ECSP109983A (es) 2010-04-30
ZA201002011B (en) 2011-05-25
EP2190412A2 (en) 2010-06-02
BRPI0815713A2 (pt) 2015-02-10
US20090092662A1 (en) 2009-04-09
MX2010002101A (es) 2010-03-26
WO2009026430A3 (en) 2009-11-26
WO2009026430A2 (en) 2009-02-26
CA2697044A1 (en) 2009-02-26
SV2010003487A (es) 2010-08-10
EA201070297A1 (ru) 2010-08-30
CO6260057A2 (es) 2011-03-22
AU2008288920A1 (en) 2009-02-26
JP2010536875A (ja) 2010-12-02
KR20100066515A (ko) 2010-06-17

Similar Documents

Publication Publication Date Title
NI201000030A (es) Formulaciones de liposomas de compuestos de ácidos borónico
UY29191A1 (es) Formulaciones liposómicas de compuestos de ácido borónico
CL2010001475A1 (es) Compuestos derivados de ester boronato, inhibidores de proteasoma; composiciones farmaceuticas que los contienen; procedimiento de preparacion de la composición farmaceutica; utiles en el tratamiento de enfermedades proliferativas celulares, en particular cancer.
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
CL2013000481A1 (es) Metodo y para mejorar la eficacia y/o reducir los efectos secundarios de una farmacoterapia administrada de forma suboptima que comprende la administracion de un hexitol sustituido; composicion farmaceutica; combinacion farmaceutica; uso para tratar enfermedades proliferativas.
UY31765A (es) Dihidropirazolonas sustituidas y su uso
ECSP12011943A (es) Antagonistas de espiro-oxindol de mdm2
DOP2013000104A (es) Antagonistas de mdm2 de espiro-oxindol
CL2013001138A1 (es) Composicion que comprende anticuerpo biespecífico cd19xcd3 para tratar masa tumoral de tejido de ganglios linfáticos y/o linfoma extranodal causado por el linfoma b difuso de células grandes (lbdcg); kit farmacéutico; uso de la composición.
CR20110324A (es) ANTICUERPO ANTI-cMET NOVEDOSO
CL2011002548A1 (es) Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica.
CR20170097A (es) Compuestos terapéuticamente activos y sus métodos de uso (divisional)
BRPI0906167A2 (pt) uso de inibidor de serina protease no tratamento de doenças de pele.
CR20130684A (es) Composición limpiadora que comprende un agente gelificante y un tensioactivo empumante
IN2014DN08886A (es)
AR086557A1 (es) Soporte de colageno enrollado
MX371143B (es) Forma farmaceutica para la liberacion prolongada de sustancias activas.
AR073089A1 (es) DERIVADOS DE (POLI)AMINOALQUILAMINOALQUILAMIDAS, ALQUIL-UREA O ALQUILSULFONAMIDA DE EPIPODOFILOTOXINA, UN PROCESO PARA PREPARARLOS, SU APLICACIoN EN TERAPIA COMO AGENTES ANTICANCER Y COMPOSICION FARMACEUTICA QUE LOS CONTIENEN.
MX2013002579A (es) Compuesto de quinoxalina.
NI201300100A (es) Derivados de tieno [2, 3-d] pirimidina y su uso para tratar arritmias
MX2012010707A (es) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos.
EA201170138A1 (ru) Соединения, используемые для профилактики или лечения аккомодационной астенопии
PA8845501A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes de curación de heridas
CL2010000899A1 (es) N1-bencil-n8-hidroxi octanodiamida; composicion farmaceutica que comprende a dicho compuesto; combinacion farmaceutica que comprende a dicho compuesto; y su uso en el tratamiento de tumores.(divisional de la solicitud 1247-04).
CR20110565A (es) Policarbonatos hiperramificados para la solubilización de sustancias activas dificilmente solubles